An interventional study of different elasticity coefficients of the manikin device in Cardiac Arrest, Sudden, Cardiopulmonary Resuscitation (CPR) and Manikins, sponsored by Tang Ziren. Completed at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Tang Ziren · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Death, Sudden, Cardiac with a site in China — 9 open to participants now, 10 under way, none of them phase 3. Death, Sudden, Cardiac · China.
Among the 19 studies in Death, Sudden, Cardiac with a site in China, this one is the only one that started in 2017, is one of 4 with no phase, and was the 19th registered.
364 studies on the registry are indexed under Death, Sudden, Cardiac; 84 are open to participants now.
Browse Death, Sudden, Cardiac studies →9 of the 19 studies in Death, Sudden, Cardiac with a site in China are open now. Recruiting first, the newest first:
Beijing Anzhen Hospital · Sites in China
Ages 18–80
Chensheng Pan · Sites in China
Ages 18+
First Affiliated Hospital Xi'an Jiaotong University · Sites in China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 16–90 · Healthy volunteers
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 63 Death, Sudden, Cardiac studies recruiting now, 42 (67%) set no upper age limit and 11 (17%) stop at 75 or younger; 22 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2017.
This study's enrollment of 183 is above the median of 126 across 135 interventional studies indexed under Death, Sudden, Cardiac.
Median enrollment 342 across the 4 interventional studies, 1,491 across the 15 observational. Of the 6 that completed or were terminated, 3 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 19 have an industry lead sponsor. The 10 most frequent:
Tang Ziren is the lead sponsor of 7 studies on the registry; 5 are open to participants now.
Tang Ziren has 1 study filed under Death, Sudden, Cardiac — fewer than ten, so there is no comparison to draw.
2 of the studies in Death, Sudden, Cardiac with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06856993The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolEarly Evaluation of Exosome Multiomics and Clinical Prognosis in Patients With Sudden Death | 2026-12-31 |
| NCT07476456China National Center for Cardiovascular DiseasesSkeletal Muscle Multi-omics Analysis and Risk Tailoring in Sudden Cardiac Death | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 19 studies in Death, Sudden, Cardiac with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study was a multicenter, prospective, randomized controlled, parallel single-blind study. The purpose of this study is to analyze the effect of compression quality by controlling the thoracic stiffness.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other: different elasticity coefficients of the manikin device
Other: different elasticity coefficients of the manikin device
Different groups used different elasticity coefficients to record participants' compression depth, frequency during the process of ECC, and recorded the data of erroneous compression.
PCCR (percentage of correct compression rate)
PCCR was defined as the percentage of chest compressions meeting guideline-recommended depth and rate criteria, calculated for each minute after initiation of chest compressions.
Time frame: At 1, 2, 3, 4, 5, and 6 minutes after initiation of chest compressions
Plan to share: Yes — All IPD that underlie results in a publication
Supporting information: Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Starting 6 months after publication
Access criteria: The de-identified survey data will be made available for research purposes by contacting the corresponding authors
No publications or documents are linked to this record.
Ran from Jan 2017 to primary completion in Jun 2018, 17 months.
Of 47 non-industry interventional studies with no phase under Death, Sudden, Cardiac, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 86. This study's 17 months is below that.
Counting every sponsor, half of 56 studies reached it within 42 months; a quarter within 17 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tang Ziren